IPO UPDATE: Bubble worries heighten after another big Alzheimer's offering
This article was originally published in Scrip
Executive Summary
Which is a bigger sign of a biotech bubble: NantKwest launching an initial public offering as the highest-value development-stage company to ever go public in the US or vTv Therapeutics raising more than $100m in an IPO to support another Alzheimer's drug candidate that was rejected by big pharma?
You may also be interested in...
Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022
Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.